A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression
Status:
Terminated
Trial end date:
2011-09-12
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to: 1) Evaluate the efficacy of CP 601,927 compared
to placebo in the augmentation of antidepressant therapy (ADT) in patients with Major
Depressive Disorder (MDD) using the Montgomery Asberg Depression Rating Scale (MADRS). 2)
Evaluate the safety and tolerability of CP 601,927 in patients with MDD on ADT.